Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rouven Müller

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
BMC Infectious Diseases|May 23, 2019
The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatientsHila Schwarz, Jürg Böni, Roger D Kouyos, et al.
Swiss Medical Weekly|October 23, 2025
Updated recommendations for diagnosis and treatment of multiple myeloma in SwitzerlandMartina Bertschinger, Holger W Auner, Veronika Ballova, et al.
Haematologica|February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapyThomas Pabst, Norbert Vey, Lionel Adès, et al.
Blood|September 2, 2016
inv(16) and NPM1mut AMLs engraft human cytokine knock-in miceJana M Ellegast, Philipp J Rauch, Larisa V Kovtonyuk, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Infection Control and Hospital Epidemiology|November 26, 2020
Absenteeism and presenteeism in healthcare workers due to respiratory illnessStefan P Kuster, Jürg Böni, Roger D Kouyos, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Infection Control and Hospital Epidemiology|May 6, 2021
Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission studyRaphaël Tamò, Teja Turk, Jürg Böni, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Blood Advances|January 4, 2018
Lymphadenopathy driven by TCR-V<sub>γ</sub>8V<sub>δ</sub>1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndromeStefano Vavassori, Jacob D Galson, Johannes Trück, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
BMC Infectious Diseases|May 23, 2019
The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatientsHila Schwarz, Jürg Böni, Roger D Kouyos, et al.
Swiss Medical Weekly|October 23, 2025
Updated recommendations for diagnosis and treatment of multiple myeloma in SwitzerlandMartina Bertschinger, Holger W Auner, Veronika Ballova, et al.
Haematologica|February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapyThomas Pabst, Norbert Vey, Lionel Adès, et al.
Blood|September 2, 2016
inv(16) and NPM1mut AMLs engraft human cytokine knock-in miceJana M Ellegast, Philipp J Rauch, Larisa V Kovtonyuk, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Infection Control and Hospital Epidemiology|November 26, 2020
Absenteeism and presenteeism in healthcare workers due to respiratory illnessStefan P Kuster, Jürg Böni, Roger D Kouyos, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Infection Control and Hospital Epidemiology|May 6, 2021
Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission studyRaphaël Tamò, Teja Turk, Jürg Böni, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Blood Advances|January 4, 2018
Lymphadenopathy driven by TCR-V<sub>γ</sub>8V<sub>δ</sub>1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndromeStefano Vavassori, Jacob D Galson, Johannes Trück, et al.
Pageof 2